National Institute of Oncolgy
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rubovszky, Gabor
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
NCT04349527: Comparison of the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Round-block and Retroglandular Oncoplastic Breast Conserving Surgeries

Recruiting
N/A
242
Europe
Round-block Oncoplastic Breast Conserving Surgeries, Retroglandular Oncoplastic Breast Conserving Surgeries
National Institute of Oncology, Hungary
Breast Cancer, Quality of Life, Patient Satisfaction
04/22
04/27
NCT05131893: Neoadjuvant Treatment of Breast Cancer

Not yet recruiting
N/A
300
Europe
Tamoxifen, Goserelin, Letrozole 2.5Mg Tab, letrozole, Epirubicin, cyclophosphamide, Docetaxel, paclitaxel, trastuzumab, pertuzumab, Capecitabine
National Institute of Oncology, Hungary
Breast Cancer
03/23
12/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rubovszky, Gabor
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
NCT04349527: Comparison of the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Round-block and Retroglandular Oncoplastic Breast Conserving Surgeries

Recruiting
N/A
242
Europe
Round-block Oncoplastic Breast Conserving Surgeries, Retroglandular Oncoplastic Breast Conserving Surgeries
National Institute of Oncology, Hungary
Breast Cancer, Quality of Life, Patient Satisfaction
04/22
04/27
NCT05131893: Neoadjuvant Treatment of Breast Cancer

Not yet recruiting
N/A
300
Europe
Tamoxifen, Goserelin, Letrozole 2.5Mg Tab, letrozole, Epirubicin, cyclophosphamide, Docetaxel, paclitaxel, trastuzumab, pertuzumab, Capecitabine
National Institute of Oncology, Hungary
Breast Cancer
03/23
12/31

Download Options